



Regenexx[®] at Work

OCTOBER 2026 | VOLUME 46

KEY TAKEAWAYS

- ✓ **An Evidence-Based Ecosystem:** Regenexx R&D built a specialized research and engineering model.
- ✓ **Long-Term Data Tracking:** The Regenexx Provider Patient Registry provides short- and long-term outcomes to track durability.
- ✓ **Continuous Quality Improvement:** Registry insights feed directly back, optimizing orthobiologics, delivery, and clinical efficacy.
- ✓ **SPECIAL EVENT: FOR CHIEF MEDICAL OFFICERS AND BENEFITS LEADERS**

 3-MINUTE READ

The Regenexx R&D Engine: Driving Musculoskeletal (MSK) Quality Through Continuous Improvement

When evaluating a musculoskeletal (MSK) benefit, plan sponsors often ask: "**Does it work?**" For self-funded employers focused on long-term cost control and patient care, a more critical question is: "**Does it work over time?**"

Orthobiologic Precision Requires Dedicated R&D

Regenexx pioneered image-guided, non-surgical orthobiologic care using a patient's own cells to treat MSK conditions. Research and engineering set Regenexx apart in three key ways:

- **Innovation:** Pioneering cell-based MSK therapies since 2005
- **Precision:** Image-guided, point-of-care delivery
- **Continuous Improvement:** Measuring, testing, and refining protocols and methodology


Unlike factory-made pharmaceuticals that deliver fixed, off-the-shelf doses in every vial, orthobiologics* depend entirely on how a patient's cells are harvested, processed, and targeted.¹⁻³

	Factory-Made Pharmaceuticals	Regenexx Orthobiologics
Source Material	Natural or synthetic chemical compounds	Patient's own living cells (PRP and/or BMC) [†]
Dosing Model	Pre-packaged, fixed concentration per vial	Optimized concentration based on procedural outcomes data ¹⁻³
Preparation	Mass-manufactured offsite	Point-of-care processing in clinic

To ensure consistency across our licensed clinical network, the Regenexx R&D team engineered the original Flexible Lab Platform and subsequent proprietary medical devices. This allows network physicians to optimize patient biologics directly at the point of care, controlling cell concentrations to support clinical efficacy.¹⁻³

The Registry Feedback Loop: Data-Driven Performance

Standardized care requires long-term accountability. Founded in 2005, the Regenexx Provider Patient Registry is the world’s oldest and largest orthobiologics outcomes database.⁴ Tracking tens of thousands of procedures network-wide over years instead of weeks, it logs patient progress, treatment efficacy, and side effects. This multi-year data stream feeds directly back into our R&D team, driving continuous protocol refinement.



The Financial Impact

Our research-driven approach turns clinical data into actionable savings for self-funded plan sponsors:

- **Avoid Unnecessary Surgeries:** Eliminates up to two-thirds of elective orthopedic procedures.⁴
- **Lower Procedure Costs:** Slashes claims cost by up to 70% on individual treatments.⁴
- **Standardized Quality:** Delivers consistent, evidence-based care across our national network.

A CLINICAL UPDATE FOR CHIEF MEDICAL OFFICERS AND BENEFITS LEADERS

The Regenexx Approach: Dose, Data and Durability

SPEAKERS:

Dr. Chaz Fausel, Chief Medical Officer
Dr. Matt Murphy, VP of Research and Development

DATE & TIME:

Friday, Oct 16, 2026 | 3:00 PM – 4:00 PM EDT

Learn how the Regenexx clinical network provides self-funded employers with a standardized, evidence-based alternative for employees who may otherwise be directed toward orthopedic surgery.



COMPLIMENTARY INVITATION
FOR OUR NEWSLETTER READERS

Why partner with the Regenexx Corporate Program?

Traditional health insurance rarely covers advanced regenerative orthopedics. The Regenexx Corporate Program bridges this gap by providing self-funded employers, brokers, and third-party administrators (TPAs) with a turnkey, \$0-cost implementation benefit that offers employees and their dependents direct access to a proven, non-surgical alternative for orthopedic pain and musculoskeletal (MSK) injuries.

Key Program and Benefit Value Drivers:

Managing musculoskeletal spend requires controlling both upfront procedure costs and long-term care utilization. The Regenexx Corporate Program delivers an evidence-based pathway that addresses both:

Validated Initial Savings: An independent cost-savings analysis by the Validation Institute confirms that procedures using Regenexx injectates average ~50% savings compared to the surgery avoided.⁵ Many program partners report reducing their costs by up to 70% on individual surgical procedures.⁴

Proven Long-Term Cost Control: Real-world commercial claims studies by Duke University researchers show Regenexx orthobiologic procedures consistently drive lower total 12- and 24-month healthcare spending compared to surgical alternatives like knee replacements, meniscectomies, and lumbar fusions.^{6,7}

True Surgery Avoidance: Duke University research confirmed that orthobiologics avert surgery instead of merely delaying it, maintaining low reoperation rates and significantly lower downstream medical utilization over multi-year follow-ups.^{6,7}

Contact your Regenexx Corporate Sales Representative to learn more.

6151 Thornton Avenue, Suite 400
Des Moines, IA 50321

regenexxcorporate.com

877.341.5968

Regenexx[®]
Corporate Program



*Orthobiologics = naturally derived substances that, when administered into bones, joints, muscles, ligaments, or tendons, can support the body's natural healing processes. The "biologics" suffix in the term "orthobiologics" is not to be confused with the way the standalone "biologics" term is used in pharmaceuticals (particularly rheumatology). In pharmaceuticals, "biologics" often refers to prescription drugs that are made by living organisms (recombinant DNA technology) or contain a component of a living organism.

[†]Bone Marrow Concentrate (BMC) contains stem cells and native growth factors.

Patients often characterize Regenexx's non-surgical treatment options as "stem cell" or "regenerative medicine" procedures using Regenexx lab processes. For more information about these terms and how Regenexx defines them, please visit <https://regenexx.com/our-approach/stem-cells/>.

Like all medical interventions, procedures using Regenexx lab processes have a success and failure rate. Regenexx provider patient reviews and testimonials in this email should not be interpreted as a statement on the effectiveness of regenerative therapy for anyone else. Industry professional reviews and testimonials reflect the experience of that entity with the Regenexx Corporate Program. To discuss what a partnership with Regenexx could look like for your company or client, contact our team.

The information provided by Regenexx is for informational purposes only and is not intended or implied to be a substitute for professional medical advice, diagnosis, or treatment. Regenexx is not a teaching institution or medical practice, and does not engage in the training of physicians or the practice of medicine. Physicians listed on the Regenexx websites are independent contractors who have licensed certain Regenexx intellectual property. Nothing on the Regenexx webpages, the Regenexx blog, any informational videos, or other marketing materials should be interpreted as endorsing a particular physician or establishing an employer-employee, partnership, or agency relationship between Regenexx and any physician.

© Regenexx Corporate 2026. All rights reserved.

References

1. Centeno C. PRP concentration vs. dose: why concentration is as important as dose. Regenexx blog. Published March 10, 2024. Accessed September 11, 2026. <https://regenexx.com/blog/prp-concentration-vs-dose-why-concentration-is-where-we-need-to-focus/>
2. Centeno C. Bone marrow stem cell dose matters in knee osteoarthritis. Regenexx blog. Published August 10, 2022. Accessed September 11, 2026. <https://regenexx.com/blog/bone-marrow-stem-cell-dose-matters-in-knee-osteoarthritis/>
3. Centeno C. Another new study says PRP dose is critical: why we have ALWAYS used high dose PRP. Regenexx blog. Published March 26, 2024. Accessed September 11, 2026. <https://regenexx.com/blog/new-study-says-prp-dose-is-critical-why-we-have-always-used-high-dose-prp/>
4. Regenexx data on file.
5. Validation Institute. Validation Report. Published 2023. Accessed May 14, 2024.
6. Lentz TA, Burrows J, Brucker A, et al. Comparative Analysis of Health Care Use and Costs for Orthobiologic versus Surgical Treatments in Economically High-Impact Knee Conditions. medRxiv. Preprint published February 27, 2026. doi:10.64898/2026.02.27.26347270
7. Lentz TA, Burrows J, Brucker A, et al. Spine-Related Health Care Utilization and Costs Following Orthobiologic Injection Versus Lumbar Surgery for Degenerative Spine Conditions. medRxiv. Preprint published March 31, 2026. doi:10.64898/2026.03.31.26349877

Note: The Duke study data have not yet been finalized by authors. This information may contain errors and report information that is not yet accepted or endorsed by the scientific or medical community. The Duke knee and spine studies were sponsored by Regenexx. Per the knee and spine study papers, the sponsor had no role in the conduct of the analyses, interpretation of the data, or manuscript preparation. Duke University investigators had full access to all study data and retained final responsibility for the content of the manuscripts and the decision to submit for publication. Both studies were retrospective, observational analyses using propensity-matched cohorts representing patients who elected orthobiologic treatment among those eligible for surgery; as with any non-randomized comparison, the potential for selection bias cannot be fully excluded.

Regenexx will never sell your information and is committed to your privacy.

No longer interested in receiving the Regenexx at Work Newsletter? Reply to this email and let us know.



6151 Thornton Avenue, Suite 400
Des Moines, IA 50321
regenexxcorporate.com
877.341.5968